Podcasts about ercc1

  • 9PODCASTS
  • 27EPISODES
  • 10mAVG DURATION
  • ?INFREQUENT EPISODES
  • Feb 24, 2021LATEST

POPULARITY

20172018201920202021202220232024


Best podcasts about ercc1

Latest podcast episodes about ercc1

CCO Oncology Podcast
Expert Insight on Key Data From WCLC 2020 in Early-Stage Lung Cancer

CCO Oncology Podcast

Play Episode Listen Later Feb 24, 2021 15:13


In this episode, Jamie E. Chaft, MD, provides her expert perspective on new data from WCLC 2020 in early-stage NSCLC, with topics including:Updated results from ADAURA on HRQoL and DFS outcomes with or without postoperative chemotherapy after adjuvant osimertinibAn analysis of the ongoing ITACA study of personalizing chemotherapy based on biomarkers of drug resistanceFDG PET/CT adaptive radiotherapy in RTOG 1106The TALENT study in Taiwan screening nonsmokers for lung cancerPresenter:Jamie E. Chaft, MDAssociate Attending PhysicianThoracic Oncology ServiceMemorial Sloan Kettering Cancer CenterNew York, New YorkContent supported by educational grants from Amgen; Bristol-Myers Squibb; Ipsen Biopharmaceuticals; Janssen Pharmaceutica NV; Jazz Pharmaceuticals; Regeneron Pharmaceuticals, Inc. & Sanofi Genzyme; and Takeda Oncology.Link to full program, including a downloadable highlights slideset, and ClinicalThought commentaries:http://bit.ly/2NzE6X6

PaperPlayer biorxiv genetics
The Splicing Factor XAB2 interacts with ERCC1-XPF and XPG for RNA-loop processing during mammalian development

PaperPlayer biorxiv genetics

Play Episode Listen Later Jul 21, 2020


Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2020.07.20.211441v1?rss=1 Authors: Goulielmaki, E., Tsekrekou, M., Batsiotos, N., Ascensao-Ferreira, M., Ledaki, E., Stratigi, K., Chatzinikolaou, G., Topalis, P., Kosteas, T., Altmuller, J., Demmers, J. A., Barbosa-Morais, N. L., Garinis, G. A. Abstract: RNA splicing, transcription and the DNA damage response are intriguingly linked in mammals but the underlying mechanisms remain poorly understood. Using an in vivo biotinylation tagging approach in mice, we show that the splicing factor XAB2 interacts with the core spliceosome and that it binds to spliceosomal U4 and U6 snRNAs and pre-mRNAs in developing livers. XAB2 depletion leads to aberrant intron retention, R-loop formation and DNA damage in cells. Studies in illudin S-treated cells and Csbm/m developing livers reveal that transcription-blocking DNA lesions trigger the release of XAB2 from all RNA targets tested. Immunoprecipitation studies reveal that XAB2 interacts with ERCC1-XPF and XPG endonucleases outside nucleotide excision repair and that the trimeric protein complex binds RNA:DNA hybrids under conditions that favor the formation of R-loops. Thus, XAB2 functionally links the spliceosomal response to DNA damage with R-loop processing with important ramifications for mammalian development and transcription-coupled DNA repair disorders. Copy rights belong to original authors. Visit the link for more info

GRACEcast ALL Subjects audio and video
Predictive Testing for Chemotherapy Responsiveness

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Feb 20, 2016 3:50


Dr. Nathan Pennell, Cleveland Clinic, evaluates chemotherapy sensitivity assays, describing the difficulties inherent in predicting response to chemotherapy agents.

GRACEcast
Predictive Testing for Chemotherapy Responsiveness

GRACEcast

Play Episode Listen Later Feb 20, 2016 3:50


Dr. Nathan Pennell, Cleveland Clinic, evaluates chemotherapy sensitivity assays, describing the difficulties inherent in predicting response to chemotherapy agents.

GRACEcast Lung Cancer Video
Predictive Testing for Chemotherapy Responsiveness

GRACEcast Lung Cancer Video

Play Episode Listen Later Feb 20, 2016 3:50


Dr. Nathan Pennell, Cleveland Clinic, evaluates chemotherapy sensitivity assays, describing the difficulties inherent in predicting response to chemotherapy agents.

ESMO Open
Highlights from the Gastrointestinal Cancers Symposium

ESMO Open

Play Episode Listen Later Feb 17, 2016 9:43


A critical review of key studies from the ASCO 2016 Gastrointestinal Cancers Symposium, held January 2016, is presented in this podcast. A number of tumor areas, including gastric, esophageal and colorectal cancers, are considered with an emphasis on recent developments in immunotherapy. Studies reviewed include the CheckMate-032 trial, which assessed the activity of the anti-PD-1 antibody nivolumab in patients with advanced gastric or gastroesophageal junction cancer, the KEYNOTE-028 trial, for which results of the esophageal carcinoma cohort treated with pembrolizumab were presented, and updated results of a trial considering PD-1 blockade in mismatch repair deficient non-colorectal gastrointestinal cancers. Biomarkers are further considered in the Mavericc trial which sought to stratify metastatic colorectal cancer patients by ERCC1 in order to predict their response to platinum-based treatments. Neoadjuvant therapy was considered with the results of a study, from the Polish Colorectal Study Group, using neoadjuvant chemoradiation for fixed cT3 or cT4 rectal cancers, and the 5-year follow up results of the ACCORD 12 trial, which aimed to assess an increased radiation dose plus oxaliplatin versus standard radiotherapy of 45 Gy with concurrent capecitabine in rectal cancer. These highlights are presented by Gerald W. Prager, Medical University of Vienna, Austria (gerald.prager@meduniwien.ac.at). The podcast is conducted by Anna Berghoff, Department of Medicine, Medical University of Vienna, Austria.

Fakultät für Biologie - Digitale Hochschulschriften der LMU - Teil 05/06
Untersuchung der gesteigerten Zytotoxizität von Trabectedin durch Hyperthermie in Tumorzellen

Fakultät für Biologie - Digitale Hochschulschriften der LMU - Teil 05/06

Play Episode Listen Later Jul 28, 2015


Adulte Weichgewebesarkome (engl. soft tissue sarcoma; STS) werden zu einer Gruppe seltener maligner und teilweise aggressiver Tumoren klassifiziert, die eine Tendenz zur Bildung von hämatogenen Fernmetastasen aufweisen. Die Kombination der Regionalen Hyperthermie mit einer Chemotherapie erwies sich in vorangegangenen Studien als eine vielversprechende Behandlungsoption beim lokalisierten Hochrisiko STS. Es wurde gezeigt, dass eine neoadjuvante Chemotherapie mit Regionaler Hyperthermie bei diesen Sarkomen das Tumoransprechen, das lokale progressionsfreie und das krankheitsfreie Überleben im Vergleich zu einer alleinigen Chemotherapie signifikant verbessert. Auf zellulärer Ebene induziert ein Hitzeschock (HS) bei klinisch relevanten Temperaturen (41,8°C/43°C) unter anderem eine temporäre Defizienz der Homologen Rekombinationsreparatur (HR), einem essentiellen Mechanismus für die fehlerfreie Reparatur von DNA-Doppelstrangbrüchen (DSB). Dies steht im Zusammenhang mit einer hitzeinduzierten proteosomalen Degradierung von BRCA2, einer unerlässlichen Komponente der HR. Trabectedin (Tr) ist eine antiproliferativ wirksame Substanz, die ursprünglich aus dem marinen Tunikat Ecteinascidia turbinata isoliert wurde. Die vielfältigen zytotoxischen Aktivitäten von Tr umfassen neben dem Interferieren mit der aktivierten Transkription und der Modulation der Tumor-Mikroumgebung hauptsächlich die Induktion von DSBs. Seit 2007 wird Tr in der Zweitlinientherapie zur Behandlung refraktärer STS, sowie bei Patienten eingesetzt, bei denen die Erstlinientherapie (Ifosfamid und/oder Doxorubicin) nicht angewendet werden kann. In Anbetracht der hitzeinduzierten Inaktivierung von BRCA2 und den DNA schädigenden Eigenschaften von Tr wurde in dieser Arbeit untersucht, ob und wie die Hyperthermie zu einer Wirkungsverstärkung der zytotoxischen Effekte von Tr beitragen kann. Tr bewirkt in vitro bei Zelllinien unterschiedlicher Sarkomentitäten (U2Os, SW872, SW982) eine dosisabhängige Reduktion des klonogenen Überlebens, das durch einen HS zusätzlich verstärkt wird. Die erhöhte antiproliferative Aktivität von Tr nach einem HS wird als thermale Chemosenitivierung definiert. Zudem konnte durch die Analyse der DNA-Verteilung bei U2Os und SW872 Zellen eine Intensivierung und Verlängerung der Tr-induzierten G2/M-Blockade nachgewiesen werden. Darüber hinaus wurden Zelllinien-spezifische Unterschiede bezüglich einer behandlungsinduzierten Apoptoseinduktion oder Senseszenzantwort identifiziert. SW872 Zellen weisen einen dosis- und temperaturabhängigen Anstieg des Anteiles apoptotischer Zellen auf, der mit einer starken Aktivierung der Effektorcaspasen 3 und 7 einhergeht. Dem entgegen gehen U2Os Zellen in eine ausgeprägte behandlungsinduzierte zelluläre Seneszenz über. Anhand der quantitativen Analyse Tr-induzierter H2AX Foci hat sich ein relevanter Anstieg an DSBs durch eine zusätzliche Hitzeexposition herausgestellt, der eine Beeinträchtigung der BRCA2-vermittelten vollständigen Assemblierung der DNA-Reparaturfoci vermuten lässt. Die Hypothese einer thermalen Chemosensitivierung gegenüber Tr durch eine hitzeinduzierte HR-Defizienz – insbesondere im Rahmen der hitzeinduzierten BRCA2 Degradierung – wurde zudem durch das Ausbleiben der hitzebedingten Verstärkung der Tr-induzierten Zytotoxizität bei BRCA2-defizienten Zellen bekräftigt. Darüber hinaus wurde durch Hochdurchsatzanalysen bestätigt, dass eine hitzevermittelte, erhöhte antiproliferative Aktivität von Tr nach einem Knockdown zahlreicher HR-spezifischer Komponenten ausbleibt. Durch Hochdurchsatzanalysen sowie durch anschließende Validierungsexperimente wurden Proteine identifiziert, die sich als relevant für weitere präklinische und klinische Untersuchungen herausgestellt haben. Die Proteine BRCA1, PARP1 und CHEK1 stellen dabei potentielle molekulare Marker für ein Tumoransprechen auf die Kombinationstherapie von Tr und Hyperthermie dar. Deren Inhibition erwies sich zudem als eine weitere Strategie, um die Effektivität der ursprünglichen Behandlung zusätzlich zu erhöhen. Darüber hinaus wurde die Funktion von FANCD2 als prädiktiver Marker und von ERCC1 als Resistenzmarker für das Therapieansprechen einer alleinigen Tr-Behandlung in vitro bestätigt. Die herausgearbeitete thermale Chemosensitivierung gegenüber Tr mit Hyperthermie durch die induzierte HR-Defizienz mittels passagerer BRCA2 Degradierung (induzierte synthetische Letalität) sowie die Identifizierung weiterer Proteine, deren medikamentöse Inhibition die Effektivität der Kombinationsbehandlung zusätzlich erhöhen könnte, eröffnen neue Möglichkeiten in der Therapie solider Tumoren.

GRACEcast ALL Subjects audio and video
ASCO Lung Cancer Highlights, Part 10: Strategies After Resistance to Crizotinib in ALK-Positive Advanced NSCLC (audio)

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Aug 26, 2013 5:45


Dr. Edward Garon, David Geffen School of Medicine at UCLA, describes the exciting developments with LDK-378 and potentially other second generation ALK inhibitors for crizotinib-resistant ALK-positive advanced NSCLC.

GRACEcast Lung Cancer Audio
ASCO Lung Cancer Highlights, Part 10: Strategies After Resistance to Crizotinib in ALK-Positive Advanced NSCLC (audio)

GRACEcast Lung Cancer Audio

Play Episode Listen Later Aug 26, 2013 5:45


Dr. Edward Garon, David Geffen School of Medicine at UCLA, describes the exciting developments with LDK-378 and potentially other second generation ALK inhibitors for crizotinib-resistant ALK-positive advanced NSCLC.

GRACEcast
ASCO Lung Cancer Highlights, Part 10: Strategies After Resistance to Crizotinib in ALK-Positive Advanced NSCLC (audio)

GRACEcast

Play Episode Listen Later Aug 26, 2013 5:45


Dr. Edward Garon, David Geffen School of Medicine at UCLA, describes the exciting developments with LDK-378 and potentially other second generation ALK inhibitors for crizotinib-resistant ALK-positive advanced NSCLC.

GRACEcast ALL Subjects audio and video
ASCO Lung Cancer Highlights, Part 9: The MADeIT Study of Predictive Biomarkers for Chemotherapy in Advanced NSCLC (video)

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Aug 23, 2013 9:49


Dr. Edward Garon, David Geffen School of Medicine at UCLA, covers the results and implications of the MADeIT phase III randomized study of preductive biomarkers ERCC1 and RRM1 in advanced NSCLC.

GRACEcast Lung Cancer Video
ASCO Lung Cancer Highlights, Part 9: The MADeIT Study of Predictive Biomarkers for Chemotherapy in Advanced NSCLC (video)

GRACEcast Lung Cancer Video

Play Episode Listen Later Aug 23, 2013 9:49


Dr. Edward Garon, David Geffen School of Medicine at UCLA, covers the results and implications of the MADeIT phase III randomized study of preductive biomarkers ERCC1 and RRM1 in advanced NSCLC.

GRACEcast ALL Subjects audio and video
ASCO Lung Cancer Highlights, Part 9: The MADeIT Study of Predictive Biomarkers for Chemotherapy in Advanced NSCLC (audio)

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Aug 23, 2013 9:49


Dr. Edward Garon, David Geffen School of Medicine at UCLA, covers the results and implications of the MADeIT phase III randomized study of preductive biomarkers ERCC1 and RRM1 in advanced NSCLC.

GRACEcast
ASCO Lung Cancer Highlights, Part 9: The MADeIT Study of Predictive Biomarkers for Chemotherapy in Advanced NSCLC (video)

GRACEcast

Play Episode Listen Later Aug 23, 2013 9:49


Dr. Edward Garon, David Geffen School of Medicine at UCLA, covers the results and implications of the MADeIT phase III randomized study of preductive biomarkers ERCC1 and RRM1 in advanced NSCLC.

GRACEcast
ASCO Lung Cancer Highlights, Part 9: The MADeIT Study of Predictive Biomarkers for Chemotherapy in Advanced NSCLC (audio)

GRACEcast

Play Episode Listen Later Aug 23, 2013 9:49


Dr. Edward Garon, David Geffen School of Medicine at UCLA, covers the results and implications of the MADeIT phase III randomized study of preductive biomarkers ERCC1 and RRM1 in advanced NSCLC.

GRACEcast Lung Cancer Audio
ASCO Lung Cancer Highlights, Part 9: The MADeIT Study of Predictive Biomarkers for Chemotherapy in Advanced NSCLC (audio)

GRACEcast Lung Cancer Audio

Play Episode Listen Later Aug 23, 2013 9:49


Dr. Edward Garon, David Geffen School of Medicine at UCLA, covers the results and implications of the MADeIT phase III randomized study of preductive biomarkers ERCC1 and RRM1 in advanced NSCLC.

GRACEcast
Is there a role for molecular markers predicting the best chemotherapy to use in lung cancer?

GRACEcast

Play Episode Listen Later Jun 10, 2013 5:39


Drs. Nate Pennell, Mary Pinder, and Jack West discuss trials presented at ASCO 2013 testing the potential value of molecular marker testing to select optimal chemo for advanced non-small cell lung cancer (NSCLC).

GRACEcast ALL Subjects audio and video
Is there a role for molecular markers predicting the best chemotherapy to use in lung cancer?

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Jun 10, 2013 5:39


Drs. Nate Pennell, Mary Pinder, and Jack West discuss trials presented at ASCO 2013 testing the potential value of molecular marker testing to select optimal chemo for advanced non-small cell lung cancer (NSCLC).

GRACEcast Lung Cancer Video
Is there a role for molecular markers predicting the best chemotherapy to use in lung cancer?

GRACEcast Lung Cancer Video

Play Episode Listen Later Jun 10, 2013 5:39


Drs. Nate Pennell, Mary Pinder, and Jack West discuss trials presented at ASCO 2013 testing the potential value of molecular marker testing to select optimal chemo for advanced non-small cell lung cancer (NSCLC).

GAP Annual Conference
Excision repair cross-complementation group 1 (ERCC1) is differentially expressed according to smoking status and tumor stage i

GAP Annual Conference

Play Episode Listen Later Jul 3, 2012 2:51


GRACEcast Lung Cancer Video
Q and A Session on The Emerging Role of Molecular Markers in NSCLC: a Webinar by Dr. Nathan Pennell (video)

GRACEcast Lung Cancer Video

Play Episode Listen Later Mar 7, 2010 14:44


Q&A Session following webinar with Dr. Nathan Pennell, medical oncologist and lung cancer expert at the Cleveland Clinic Foundation, on the use of molecular markers such as EGFR, KRAS, ERCC-1, EML4-ALK, and others in NSCLC.

GRACEcast Lung Cancer Audio
Q and A Session on The Emerging Role of Molecular Markers in NSCLC: a Webinar by Dr. Nathan Pennell (audio)

GRACEcast Lung Cancer Audio

Play Episode Listen Later Mar 7, 2010 14:45


Q&A Session following webinar with Dr. Nathan Pennell, medical oncologist and lung cancer expert at the Cleveland Clinic Foundation, on the use of molecular markers such as EGFR, KRAS, ERCC-1, EML4-ALK, and others in NSCLC.

GRACEcast Lung Cancer Audio
The Emerging Role of Molecular Markers in Non-Small Cell Lung Cancer: a Webinar by Dr. Nathan Pennell (audio)

GRACEcast Lung Cancer Audio

Play Episode Listen Later Jan 30, 2010 35:03


Dr. Nathan Pennell, medical oncologist and lung cancer expert at the Cleveland Clinic Foundation, reviews the current evidence and future directions for use of molecular markers such as EGFR, KRAS, ERCC-1, EML4-ALK, and others in NSCLC.    

GRACEcast Lung Cancer Video
The Emerging Role of Molecular Markers in Non-Small Cell Lung Cancer: a Webinar by Dr. Nathan Pennell (video)

GRACEcast Lung Cancer Video

Play Episode Listen Later Jan 30, 2010 35:01


Dr. Nathan Pennell, medical oncologist and lung cancer expert at the Cleveland Clinic Foundation, reviews the current evidence and future directions for use of molecular markers such as EGFR, KRAS, ERCC-1, EML4-ALK, and others in NSCLC.

GRACEcast Lung Cancer Video
Individualizing Treatment for NSCLC Based on Molecular Factors (video)

GRACEcast Lung Cancer Video

Play Episode Listen Later Dec 16, 2009 10:56


This slide presentation by Dr. George Simon, Director of Thoracic Oncology at Fox Chase Cancer Center, describes emerging molecular variables that are being studied to optimize individualized selection of systemic treatments for NSCLC.

GRACEcast Lung Cancer Audio
Individualizing Treatment for NSCLC Based on Molecular Factors (audio)

GRACEcast Lung Cancer Audio

Play Episode Listen Later Dec 16, 2009 10:58


This slide presentation by Dr. George Simon, Director of Thoracic Oncology at Fox Chase Cancer Center, describes emerging molecular variables that are being studied to optimize individualized selection of systemic treatments for NSCLC.

GRACEcast Lung Cancer Audio
Interview with George Simon on Molecular Variables and Treatment Selection for NSCLC (audio)

GRACEcast Lung Cancer Audio

Play Episode Listen Later Sep 4, 2009 15:44


Dr. George Simon, medical oncologist at Fox Chase Cancer Center in Philadelphia, discusses the current evidence and emerging treatment patterns related to molecular variables in treatment of NSCLC.